Fig. 4. Comparison of immunotherapy and non-immunotherapy in aNSCLC patient groups.

Immunotherapy versus non-immunotherapy is compared as (a) first-line and (b) second-line therapies in four aNSCLC patient groups consisting of patients with tumor mutation burden (TMB) low and Random Survival Forest (RSF) score low, patients with TMB low and RSF score high, patients with TMB high and RSF score low, and patients with TMB high and RSF score high. The circle sizes represent the percentage of patients in each group. The circle colors represent the overall survival hazard ratio (HR) for patients who received immunotherapy vs. non-immunotherapy as a. first-line and b. second-line therapy. Cross-validation standard deviation is reported for each HR.